GlassScriptPhysician profile
Ji H Chun
NPI 1982912945
$2,366.91
in general payments reported to CMS, 2019-2025
19 companies · $804 in 2025
The $804 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $843 · 2024: $470 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $316.58 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $289.25 | 2023-2025 | |
| Corcept Therapeutics | $236.23 | 2023-2025 | Korlym |
| Amgen INC. | $180.18 | 2025 | Tepezza, Evenity, Prolia |
| Apellis Pharmaceuticals, INC. | $144.88 | 2025 | |
| Mannkind Corporation | $144.42 | 2023-2025 | Afrezza |
| Dexcom, INC. | $135.39 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $130.53 | 2023-2025 | Sogroya, Wegovy, Rybelsus |
| Horizon Therapeutics Plc | $124.13 | 2023 | Tepezza |
| Esperion Therapeutics, INC. | $109.18 | 2024 | Nexletol |
| Ascendis Pharma Endocrinology INC | $107.71 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $102.52 | 2022 | |
| Insulet Corporation | $98.64 | 2023-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.75 | 2022-2023 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $61.58 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.25 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $23.76 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2022 | |
| Cequr Corporation | $10.94 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.